Pfizer-Allergan deal would set up U.S. company for a split

A Pfizer Inc merger with Ireland-based Allergan , in addition to providing tax benefits, would bolster the U.S. drugmaker's growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent. Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling three years of financial data treating its "established products" division, which sells generic medicines, and its "innovative" patent-protected medicines unit, as if they wer